ARBs don't stop atrial fibrillation recurrence
ARBs may not prevent atrial fibrillation from recurring, contrary to the results of early experimental studies, new US research suggests.
In a randomised controlled trial, 1,400 patients with atrial fibrillation were given either valsartan or placebo.
There was no significant difference in the recurrence of atrial fibrillation in patients in the valsartan and placebo groups. Atrial fibrillation recurred in 51.4% of the valsartan group compared with 52.1% in the placebo group.